[SUNY Downstate affiliation]  Utilizing a novel immunologic approach, NomoCan Pharmaceuticals is developing a targeted therapy for the treatment and prognosis of the most aggressive human cancer, pancreatic cancer.  NomoCan Executive Summary

No Comments Yet.

Leave a Reply

You must be logged in to post a comment.